Irritable Bowel Syndrome (IBS)

Back

Practice Essentials

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterized by abdominal pain and altered bowel habit in the absence of a specific and unique organic pathology, although microscopic inflammation has been documented in some patients.[1] Population-based studies estimate the prevalence of irritable bowel syndrome at 10%-20% and the incidence of irritable bowel syndrome at 1%-2% per year.

Signs and symptoms

Manifestations of IBS are as follows:

Altered bowel habit in IBS may have the following characteristics:

Abdominal pain in IBS is protean, but may have the following characteristics:

Additional symptoms consistent with irritable bowel syndrome are as follows:

Symptoms not consistent with irritable bowel syndrome should alert the clinician to the possibility of an organic pathology. Inconsistent symptoms include the following:

See Presentation for more detail.

Diagnosis

The Rome IV criteria for the diagnosis of irritable bowel syndrome require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following[2] :

The Rome IV criteria (May 2016) only require abdominal pain in defining this condition; "discomfort" is no longer a requirement owing to its nonspecificity, and the recurrent abdominal pain.[2]

Supporting symptoms include the following:

Four bowel patterns may be seen with irritable bowel syndrome, and these remain in the Rome IV classification.[2] These patterns include the following:

The usefulness of these subtypes is debatable. Notably, within 1 year, 75% of patients change subtypes, and 29% switch between constipation-predominant IBS and diarrhea-predominant IBS. The Rome IV criteria differ from the Rome III criteria in basing bowel habit on stool forms solely during days with abnormal bowel movements rather than on the total number of bowel movements.[2]

A comprehensive history, physical examination, and tailored laboratory and radiographic studies can establish a diagnosis of irritable bowel syndrome in most patients. The American College of Gastroenterologists does not recommend laboratory testing or diagnostic imaging in patients younger than 50 years with typical IBS symptoms and without the following “alarm features”[3] :

Screening studies to rule out disorders other than IBS include the following:

History-specific studies include the following:

See Workup for more detail.

Management

Management of irritable bowel syndrome consists primarily of providing psychological support and recommending dietary measures. Pharmacologic treatment is adjunctive and should be directed at symptoms.

Dietary measures may include the following:

Although the evidence is mixed regarding long-term improvement in GI symptoms with successful treatment of psychiatric comorbidities, the American College of Gastroenterology has concluded the following:

Pharmacologic agents used for the management of symptoms in IBS include the following:

See Treatment and Medication for more detail.



View Video

What is irritable bowel syndrome (IBS)? IBS is a condition that involves recurrent abdominal pain as well as abnormal bowel motility, which can include diarrhea and/or constipation.

Background

Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder characterized by abdominal pain and altered bowel habit in the absence of a specific and unique organic pathology. Osler coined the term mucous colitis in 1892 when he wrote of a disorder of mucorrhea and abdominal colic with a high incidence in patients with coincident psychopathology. Since then, the syndrome has been referred to by sundry terms, including spastic colon, irritable colon, and nervous colon.

In the past, irritable bowel syndrome has been considered a diagnosis of exclusion; however, it is no longer considered a diagnosis of exclusion, but it does have a broad differential diagnosis.[7] No specific motility or structural correlates have been consistently demonstrated; however, experts suggest that the use of available guidelines can minimize testing and aid in the diagnosis.

Pathophysiology

Traditional theories regarding the pathophysiology of irritable bowel syndrome (IBS) may be visualized as a three-part complex of altered gastrointestinal (GI) motility, visceral hyperalgesia, and psychopathology.[8] More recently, it is believed that components of the gut microbiota potentially influence brain morphology and function, behavior, and cognition, which expands the paradigm of the gut-brain axis.[9] A unifying mechanism is still unproven.

Altered GI motility

Altered GI motility includes distinct aberrations in the small and large bowel motility.

The myoelectric activity of the colon is composed of background slow waves with superimposed spike potentials. Colonic dysmotility in irritable bowel syndrome manifests as variations in slow-wave frequency and a blunted, late-peaking, postprandial response of spike potentials. Patients who are prone to diarrhea demonstrate these alterations to a greater degree than patients who are prone to constipation.

Small bowel dysmotility manifests in delayed meal transit in patients prone to constipation and in accelerated meal transit in patients prone to diarrhea. In addition, patients exhibit shorter intervals between migratory motor complexes (the predominant interdigestive small bowel motor patterns).

Current theories integrate these widespread motility aberrations and hypothesize a generalized smooth muscle hyperresponsiveness. They describe increased urinary symptoms, including frequency, urgency, nocturia, and hyperresponsiveness to methacholine challenge.

Visceral hyperalgesia

Visceral hyperalgesia is the second part of the traditional three-part complex that characterizes irritable bowel syndrome.[10]

Enhanced perception of normal motility and visceral pain characterizes irritable bowel syndrome. Rectosigmoid and small bowel balloon inflation produces pain at lower volumes in patients than in controls. Notably, hypersensitivity appears with rapid but not with gradual distention.

Patients who are affected describe widened dermatomal distributions of referred pain. Sensitization of the intestinal afferent nociceptive pathways that synapse in the dorsal horn of the spinal cord provides a unifying mechanism.

Psychopathology

Psychopathology is the third aspect. Associations between psychiatric disturbances and irritable bowel syndrome pathogenesis are not clearly defined.

Patients with psychological disturbances relate more frequent and debilitating illness than control populations. Patients who seek medical care have a higher incidence of panic disorder, major depression, anxiety disorder, and hypochondriasis than control populations. A study has suggested that patients with irritable bowel syndrome may have suicidal ideation and/or suicide attempts strictly as a result of their bowel symptoms.[11] Clinical alertness to depression and hopelessness is mandatory. This is underscored by another study that revealed that patient complaints that relate to functional bowel disorders may be trivialized.

An Axis I disorder coincides with the onset of GI symptoms in as many as 77% of patients. A higher prevalence of physical and sexual abuse has been demonstrated in patients with irritable bowel syndrome. Whether psychopathology incites the development of irritable bowel syndrome or vice versa remains unclear.

Microscopic inflammation

Microscopic inflammation has been documented in some patients.[1] This concept is groundbreaking in that irritable bowel syndrome had previously been considered to have no demonstrable pathologic alterations.

Both colonic inflammation and small bowel inflammation have been discovered in a subset of patients with irritable bowel syndrome, as well as in patients with the onset of irritable bowel syndrome after infectious enteritis (postinfectious irritable bowel syndrome). Risk factors for developing postinfectious irritable bowel syndrome include longer duration of illness, the type of pathogen involved, smoking, female gender, an absence of vomiting during the infectious illness, and young age.[12]

Laparoscopic full-thickness jejunal biopsy samples revealed infiltration of lymphocytes into the myenteric plexus and intraepithelial lymphocytes in a subset of patients in one study.[13] Neuronal degeneration of the myenteric plexus was also present in some patients.

Patients with postinfectious irritable bowel syndrome may have increased numbers of colonic mucosal lymphocytes and enteroendocrine cells. Enteroendocrine cells in postinfectious irritable bowel syndrome appear to secrete high levels of serotonin, increasing colonic secretion and possibly leading to diarrhea.

Alterations in the intestinal biome

Small bowel bacterial overgrowth has been heralded as a unifying mechanism for the symptoms of bloating and distention, common to patients with irritable bowel syndrome. This has led to proposed treatments with probiotics and antibiotics.

The fecal microflora also differs among patients with irritable bowel syndrome versus controls. A sophisticated molecular analysis suggested an alteration in the patterns and the contents of gut bacteria.[14]

Etiology

The causes of irritable bowel syndrome remain poorly defined, but they are being avidly researched.

Postulated etiologies of irritable bowel syndrome

Abnormal transit profiles and an enhanced perception of normal motility may exist. Up to one third of patients with irritable bowel syndrome may have altered colonic transit. Delayed colonic motility may be more common in patients with constipation-predominant irritable bowel syndrome than in healthy controls. Similarly, accelerated colonic transit may be more common in patients with diarrhea-predominant disease than in healthy controls.[15] Local histamine sensitization of the afferent neurons causing earlier depolarization may occur.

Causes related to enteric infection

Colonic muscle hyperreactivity and neural and immunologic alterations of the colon and small bowel may persist after gastroenteritis. Psychological comorbidity independently predisposes the patient to the development of postinfectious irritable bowel syndrome. Psychological illness may create a proinflammatory cytokine milieu, leading to irritable bowel syndrome through an undefined mechanism after acute infection.

Infection with Giardia lamblia has been shown to lead to an increased prevalence of irritable bowel syndrome, as well as chronic fatigue syndrome. In a historic cohort study of patients with G lamblia infection as detected by stool cysts, the prevalence of irritable bowel syndrome was 46.1% for as long as 3 years after exposure, compared with 14% in controls.[16]

Central neurohormonal mechanisms

Abnormal glutamate activation of N- methyl-D- aspartate (NMDA) receptors, activation of nitric oxide synthetase, activation of neurokinin receptors, and induction of calcitonin gene–related peptide have been observed.

The limbic system mediation of emotion and autonomic response enhances bowel motility and reduces gastric motility to a greater degree in patients who are affected than in controls. Limbic system abnormalities, as demonstrated by positron emission tomography, have been described in patients with irritable bowel syndrome and in those with major depression.

The hypothalamic-pituitary axis may be intimately involved in the the pathogenesis of IBS. Motility disturbances correspond to an increase in hypothalamic corticotropin-releasing factor (CRF) production in response to stress. CRF antagonists eliminate these changes.

Additional etiologic factors

Intestinal permeability

Intestinal permeability appears to be increased, especially in diarrhea-predominant irritable bowel syndrome.[17]

Alterations in the intestinal biome

As discussed in Pathophysiology, Pimentel and colleagues have proposed that small bowel bacterial overgrowth provides a unifying mechanism for the common symptoms of bloating and gaseous distention in patients with irritable bowel syndrome.[18]

There is a relationship between the organisms that live in the intestine and the immune system, and this relationship is not yet fully understood.[17, 19]

Dietary intolerance

Bloating and distention may also occur from intolerance to dietary fats. Reflex-mediated small bowel gas clearance is more impaired by the ingestion of lipids in patients with irritable bowel syndrome than in patients without the disorder.

Studies of elimination and challenge diets have suggested that poorly absorbed short-chain carbohydrates, in the form of fructose and fructans, may create symptoms among adult patients with irritable bowel syndrome, as measured by a visual analogue scale.[20] Fructans have also been found to exacerbate the symptoms (abdominal pain, bloating, hydrogen production) in a subset of children with irritable bowel syndrome, but fructan sensitivity could not be identified on the basis of baseline gastrointestinal symptoms, dietary intake, psychosocial factors, or gas production.[21]

Evidence exists showing an association between functional variants in the sucrase-isomaltase (SI) gene and an increased risk of irritable bowel syndrome. In one study, investigators sequenced SI exons in seven familial cases, as well as screened for four congenital sucrase-isomaltase deficiency (CSID) mutations and a common SI coding polymorphism in a multicenter cohort comprised of 1887 patients and control subjects, and found that individuals affected by the SI mutations that code for defective or enzymatic activity in disaccharides had a predisposition to irritable bowel syndrome.[22] Similarly, another multinational genotype study of 2207 patients indicates that there is an increased prevalence of rare sucrase-isomaltase pathogenic variants in those affected by irritable bowel syndrome.[23]

Research suggests that neuronal degeneration and myenteric plexus lymphocytosis may exist in the proximal jejunum. Additionally, colonic lymphocytosis and enteroendocrine cell hyperplasia have been demonstrated in some patients.

Epidemiology

Population-based studies estimate the prevalence of irritable bowel syndrome (IBS) at 10%-20%[24] and the incidence of irritable bowel syndrome at 1%-2% per year. However, when a 2016 population-based study compared the prevalence of irritable bowel syndrome with the Rome IV criteria versus the Rome III criteria in the United States, Canada, and the United Kingdom, investigators reported a nearly 50% reduction in its prevalence in these countries—potentially attributable to removing "discomfort" from the definition.[25]

Of people with irritable bowel syndrome, approximately 10%-20% seek medical care. An estimated 20%-50% of gastroenterology referrals relate to this symptom complex. The incidence is markedly different among countries.

American and European cultures demonstrate similar frequencies of irritable bowel syndrome across racial and ethnic lines. However, within the United States, survey questionnaires indicate a lower prevalence of irritable bowel syndrome in Hispanics in Texas and Asians in California. Populations of Asia and Africa may have a lower prevalence of irritable bowel syndrome. The role of different cultural influences and varying health care–seeking behaviors is unclear.

Adolescent and young adult women are most commonly affected.[9] In Western countries, women are 2-3 times more likely to develop irritable bowel syndrome than men, although males represent 70%-80% of patients with irritable bowel syndrome in the Indian subcontinent. Women seek health care more often, but the irritable bowel syndrome–specific influence of this occurrence remains unknown. Other factors, such as a probably greater incidence of abuse in women, may confound interpretation of this statistic.

Patients often retrospectively note the onset of abdominal pain and altered bowel habit in childhood. Approximately 50% of people with irritable bowel syndrome report symptoms beginning before age 35 years. The development of symptoms in people older than 40 years does not exclude irritable bowel syndrome but should prompt a closer search for an underlying organic etiology.

Prognosis

Irritable bowel syndrome is a chronic relapsing disorder characterized by recurrent symptoms of variable severity; however, life expectancy remains similar to that of the general population. Clinicians must be forthcoming with patients because knowledge of the condition may help allay undue fears as their disease waxes and wanes. Irritable bowel syndrome (IBS) does not increase mortality, or the risk of inflammatory bowel disease or cancer.

Patients with irritable bowel syndrome may carry an increased risk of ectopic pregnancy and miscarriage, but not stillbirth. The reasons for this are unknown. Whether the risk increases because of IBS itself, or because of another factor such as medications used for irritable bowel syndrome, is unknown.[26]

The principal associated physical morbidities of irritable bowel syndrome include abdominal pain and lifestyle modifications secondary to altered bowel habits. Work absenteeism resulting in lost wages is more frequent in patients with irritable bowel syndrome.

There appears to be an increased prevalence of comorbid anxiety and depression among patients with IBS, and these are associated with lower socioeconomic status and lower average per capita income.[27] Clinicians therefore should consider a biopsychosocial model of illness in these patients.

Patient Education

Patient education remains the cornerstone of successful treatment of irritable bowel syndrome. Teach the patient to identify stressors and to develop avoidance techniques. Many patients successfully manage their symptoms with attention to dietary triggers.

For patient education resources, see Digestive Disorders Center, as well as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), and Chronic Pain.

Clinicians may also wish to refer patients to the following short video, which provides a simplified but clear and concise overview about what irritable bowel syndrome is, and its epidemiology, risk factors, and management options, as well as a brief explanation of the difference between irritable bowel syndrome and inflammatory bowel disease.



View Video

What is irritable bowel syndrome (IBS)? IBS is a condition that involves recurrent abdominal pain as well as abnormal bowel motility, which can include diarrhea and/or constipation.

History and Physical Examination

History

A meticulous history is the key to establish a diagnosis of irritable bowel syndrome, which comprises a range of manifestations and aggravation factors.[9]  Indeed, there is a great deal of interindividual symptomatic variability among affected patients, which a detailed symptomatic history may aid in identifying distinct symptom subgroups and thus guide symptom management.[28] The Rome criteria provide the construct upon which questions are based (see Diagnostic Considerations).

Altered bowel habits

Constipation results in complaints of hard stools of narrow caliber, painful or infrequent defecation, and intractability to laxatives. Diarrhea usually is described as small volumes of loose stool, with evacuation preceded by urgency or frequent defecation. Postprandial urgency is common, as is alternation between constipation and diarrhea. Characteristically, one feature predominates in a single patient, but significant variability exists among patients.

Abdominal pain

Descriptions are protean. Pain frequently is diffuse without radiation. Common sites of pain include the lower abdomen, specifically the left lower quadrant. Acute episodes of sharp pain are often superimposed on a more constant dull ache. Meals may precipitate pain, and defecation commonly improves pain. Defecation may not fully relieve pain, however.

Pain from presumed gas pockets in the splenic flexure may masquerade as anterior chest pain or left upper quadrant abdominal pain. This splenic flexure syndrome is demonstrable by balloon inflation in the splenic flexure and should be considered in the differential of chest or left upper quadrant abdominal pain.

Abdominal bloating/distention

Patients frequently report increased amounts of bloating and gas. Quantitative measurements fail to support this claim. People with irritable bowel syndrome may manifest increasing abdominal circumference throughout the day, as assessed by computed tomography (CT) scan. They may also demonstrate intolerance to otherwise normal amounts of abdominal distention.

Additional symptoms consistent with irritable bowel syndrome

Clear or white mucorrhea of a noninflammatory etiology is commonly reported. Epidemiologic associations with dyspepsia, heartburn, nausea, vomiting, sexual dysfunction (including dyspareunia and poor libido), and urinary frequency and urgency have been noted. Symptoms may worsen in the perimenstrual period, and fibromyalgia is a common comorbidity. Stressor-related symptoms may be revealed with careful questioning (emphasize avoidance of stressors).

Symptoms inconsistent with irritable bowel syndrome

Symptoms not consistent with irritable bowel syndrome should alert the clinician to the possibility of an organic pathology. Inconsistent symptoms include the following:

Physical examination

The patient with irritable bowel syndrome has an overall healthy appearance but may be tense or anxious. The patient may present with sigmoid tenderness or a palpable sigmoid cord.

Criteria for Diagnosis

A consensus panel created and continually updates the Rome diagnostic criteria to provide a standardized diagnosis for research and clinical practice. The Rome IV criteria for the diagnosis of irritable bowel syndrome (IBS) were released in 2016 and require that patients have had recurrent abdominal pain on average at least 1 day per week during the previous 3 months that is associated with two or more of the following[2] :

Unlike the Rome III criteria, the Rome IV criteria only require abdominal pain in defining this condition; "discomfort" is no longer included owing to its ambiguity and different meanings across cultures and languages.[2]

Supporting symptoms include the following:

Four bowel patterns may be seen with irritable bowel syndrome, and these remain unchanged in the Rome IV classification.[2] These patterns include the following:

The usefulness of these subtypes is debatable. Notably, within 1 year, 75% of patients change subtypes, and 29% switch between constipation-predominant IBS and diarrhea-predominant IBS. The Rome IV criteria differ from the Rome III criteria in basing bowel habits on stool forms solely during days with abnormal bowel movements rather than on the total number of bowel movements.[2]

Approach Considerations

A comprehensive history, physical examination, and tailored laboratory and radiographic studies can establish a diagnosis of irritable bowel syndrome in most patients. The specificity of the Rome III criteria may be improved by including information about nocturnal stools, somatization, and affective disorders on the basis of the clinical history as well as including hemoglobin and C-reactive protein levels with other diagnostic studies.[30]  Routine serologic or genetic testing is not indicated in patients with irritable bowel syndrome (IBS) in all US populations as it appears that celiac disease is uncommon in IBS in this country.[31]

The 2009 American College of Gastroenterologists (ACG) evidence-based position statement on the management of IBS does not recommend laboratory testing or diagnostic imaging in patients younger than 50 years with typical IBS symptoms and without “alarm features”. Alarm features include the following symptoms and history[3] :

Although rectal bleeding and nocturnal symptoms have also been considered alarm features, they are not specific for organic disease. Patients with IBS-D or IBS-M should have serologic testing for celiac sprue. Patients aged 50 years and older should have more extensive testing, including a colonoscopy.[3]

Laboratory Studies

Blood studies

A complete blood cell (CBC) count with differential to screen for anemia, inflammation, and infection is indicated. A comprehensive metabolic panel to evaluate for metabolic disorders and to rule out dehydration/electrolyte abnormalities in patients with diarrhea is also indicated.

Stool examinations

Microbiologic studies to consider include the following stool examinations:

History-Specific Examinations

Hydrogen breath testing to exclude bacterial overgrowth may be considered in patients with diarrhea to screen for lactose and/or fructose intolerance. Tissue transglutaminase antibody testing and small bowel biopsy are used especially in diarrhea-predominant irritable bowel syndrome to diagnose celiac disease.

Thyroid function tests are used to screen for hyperthyroidism or hypothyroidism. Serum calcium testing is used to screen for hyperparathyroidism.

Erythrocyte sedimentation rate and C-reactive protein measurement are nonspecific screening tests for inflammation.

History-Specific Imaging Studies

Gallbladder ultrasonography should be considered if the patient has recurrent dyspepsia or characteristic postprandial pain.

Abdominal computed tomography (CT) scanning is appropriate to screen for tumors, obstruction, and pancreatic disease if these are diagnostic possibilities.

CT and magnetic resonance (MR) enterography or wireless capsule endoscopy are employed if red flags exist to suggest enteritis (small bowel inflammation) or a tumor.

Colonoscopy is appropriate if alarm symptoms are present and in patients who otherwise qualify for screening colonoscopy.

Dietary Studies

Employ a lactose-free diet for 1 week in conjunction with lactase supplements. Improvement incriminates lactose intolerance, although the patient's clinical history and response to a trial may be unreliable. Therefore, some gastroenterologists recommend a formal hydrogen breath test. Fructose intolerance must also be considered.

Breath testing may also be used to evaluate for small intestinal bacterial overgrowth, as formal jejunal aspiration is rarely performed anymore.

Other dietary intolerances include FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols), gluten, and fructose. Low FODMAP diets can be helpful in this situation, though may be found very restrictive.

History-Specific Procedures

Anal manometry may reveal a spastic response to rectal distention or other problems. For many patients with irritable bowel syndrome, endoscopy appropriately includes flexible sigmoidoscopy to assess for inflammation or distal obstruction.

Esophagogastroduodenoscopy with possible biopsy is indicated in patients with persistent dyspepsia, if weight loss or symptoms suggest malabsorption, or if celiac disease is a concern. Colonoscopy is indicated for patients with warning signs, such as bleeding; anemia; chronic diarrhea; older age; history of colon polyps; cancer in the patient or first-degree relatives; or constitutional symptoms, such as weight loss or anorexia. A screening colonoscopy should be performed according to published guidelines.

Approach Considerations

Management of irritable bowel syndrome consists primarily of providing psychological support and recommending dietary measures. Pharmacologic treatment is adjunctive and should be directed at symptoms, such as modulation of persistent visceral hyperalgesia.[10]

The 2009 American College of Gastroenterologists (ACG) position statement recommends addressing nongastrointestinal symptoms and comorbidities to improve health-related quality of life as well as to reduce symptom severity. Evidence considered in the position statement was insufficient to recommend exclusion diets or food allergy testing.[3]

The 2014 ACG monograph on the management of irritable bowel syndrome and chronic idiopathic constipation found insufficient evidence to recommend prebiotics or synbiotics, or loperamide, in irritable bowel syndrome, and no evidence that polyethylene glycol improved overall symptoms and pain in affected patients.[32] There was high quality of evidence to support the use of antidepressants as a class, and moderate quality of evidence in favor of fiber and psyllium, for overall symptomatic relief in irritable bowel syndrome. Strong recommendations were reported for linaclotide and lubiprostone each being superior to placebo in treating the constipation-predominant disease subtype.[32]

Successful management relies on a strong patient-provider relationship. Reassure the patient that the absence of an organic pathology indicates a normal life expectancy. Emphasize the expected chronicity of symptoms with periodic exacerbations. Teach the patient to identify stressors and to use avoidance techniques.

Dietary Measures

Fiber supplementation may improve symptoms of constipation and diarrhea. Individualize the treatment because a few patients experience exacerbated bloating and distention with high-fiber diets. Polycarbophil compounds (eg, Citrucel, FiberCon) may produce less flatulence than psyllium compounds (eg, Metamucil).

The data regarding the effectiveness of fiber are controversial because 40%-70% of patients improve with placebo. A Cochrane systematic review found no benefit of fiber/bulking agents on irritable bowel syndrome symptoms or global assessment.[33]

Judicious water intake is recommended in patients who predominantly experience constipation.

Caffeine avoidance may limit anxiety and symptom exacerbation. Legume avoidance may decrease abdominal bloating. Lactose and/or fructose should be limited or avoided in patients with these contributing disorders. Take care to supplement calcium in patients limiting their lactose intake.

Gluten intolerance has been associated with irritable bowel syndrome. In a small but important study, patients with irritable bowel syndrome who were well-controlled on a gluten-free diet were rechallenged in a double-blind fashion.[34] Approximately two thirds of these patients had poor symptom control with rechallenge. As with many irritable bowel syndrome studies, the placebo response was high (40%). Notably, neither intestinal inflammation nor permeability was different among the groups, and no difference in the positivity rate for celiac disease–related HLA haplotypes or antibody markers was noted. Volta et al evaluated the current evidence and suggest that patients with gluten/wheat sensitivity may be a subset of those with irritable bowel syndrome.[35]

Many patients are interested in dietary manipulation to decrease their symptoms. Several different diets have been proposed.[36] Diets low in FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) hold particular interest in reducing symptoms of irritable bowel syndrome.[37] Investigators found 10 of 54 bacterial markers differed significantly between 32 patients who responded to FODMAPs and 29 who did not; using their findings, they developed a response index that assesses gut microbial composition and has the potential to identify patients who are more likely to respond to a dietary FODMAP restriction.[38] In a preclinical, murine study, a low-FODMAP diet did not appear to exacerbate nor mitigate inflammation on a postinflammatory model of IBS.[39] However, a retrospective study (2013-2016) comprising data from 164 Irish patients with IBS found that a low-FODMAP diet provided significant all-symptomatic improvement at 3-, 6-, and 12-month follow-up.[40]

Probiotics are very interesting for treating symptoms, but it is unclear for which patients probiotics are helpful, and in what form, dose, combination, or strain.[41, 42, 43] A meta-analysis concluded that Bifidobacterium infantis may help alleviate some symptoms of irritable bowel syndrome.[44]

A systematic review and meta-analysis of 13 articles that assessed the differential expression of intestinal microbiota in 360 patients with this condition compared to 268 healthy controls found downregulation of bacterial colonization of Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii in patients with irritable bowel syndrome.[45] Those with the diarrhea-predominant subtype had significantly different expression of Lactobacillus and Bifidobacterium. A different systematic review and meta-analysis evaluated 43 articles on probiotics and showed that probiotics helped relieve pain, bloating, and gas[46] ; however, again, it remains unknown which probiotic is the best.

A European multicenter pilot study that evaluated the effectiveness of palmitoylethanolamide/polydatin in 54 patients with irritable bowel syndrome compared to 12 healthy controls did not show any significant changes in modifying the biologic profile of the condition (eg, mast cell count); however, this combination significantly improved the severity of abdominal pain when compared to placebo.[47]

In a study of 998 adolescent Iranian girls, investigators noted a 16.9% prevalence of irritable bowel syndrome and identified several factors that appeared to be associated with an increased risk of this condition, including intrameal fluid consumption, consumption of spicy and fried food, insufficient chewing, and greater loss of teeth (≥5 teeth).[48]

Psychological Therapy

Consider psychiatric referral. Previous evidence supported improvement in gastrointestinal (GI) symptoms with successful treatment of psychiatric comorbidities, but studies by Zijdenbos et al and Ford et al indicate that caution should be used when interpreting such data.[49, 50]

In a meta-analysis by Zijdenbos et al of 25 randomized trials consisting of single psychological interventions with usual care or mock intervention in patients older than 16 years, the authors found that although cognitive-behavioral therapy and interpersonal psychotherapy were effective immediately after treatment completion, there was no convincing evidence for sustained benefits with any treatment modality. Thus, Zijdenbos et al recommended that future research should focus on current irritable bowel syndrome treatment guidelines and their long-term effects.[49]

Ford et al reached similar conclusions regarding the use of psychological interventions in irritable bowel syndrome. The authors concluded that antidepressants are effective in the treatment of irritable bowel syndrome, but although the available data suggest that psychological therapies may be of comparable efficacy, there is less high-quality evidence for the routine use of psychological therapies in patients with IBS. They performed a systematic review and meta-analysis of randomized controlled trials in adults with IBS; however, their selection criteria included trials comparing antidepressants with placebo as well as those comparing psychological therapies with control therapy or usual care. The investigators noted that the quality of studies were generally good for those involving antidepressants but poor for those involving psychological therapy.[50]

A Cochrane systematic review determined that antidepressants improved both irritable bowel symptoms and global assessment scores compared with placebo. Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants were both shown to be effective in subgroup analyses.[33]

The 2009 American College of Gastroenterologists (ACG) position statement concluded that psychological interventions, cognitive behavioral therapy, dynamic psychotherapy, and hypnotherapy, are more effective than placebo. Relaxation therapy was no more effective than usual care. In agreement with the above analysis, study quality was described as low.[3]

More recent studies suggest targeting the mediating psychological process involved in patients with irritable bowel syndrome, such as illness perceptions, maladaptive coping, and visceral sensitivity.[24]

Long-term Monitoring

Frequent visits with the clinician enhance the patient-provider relationship, especially in patients who were recently diagnosed with irritable bowel syndrome. Visits can become less frequent as patients are educated and reassured.

Medication Summary

The selection of pharmacologic treatment remains symptom directed. Agents used for the management of symptoms in irritable bowel syndrome (IBS) include anticholinergics, antidiarrheals, tricyclic antidepressants, prokinetic agents, bulk-forming laxatives, serotonin receptor antagonists, chloride channel activators, and guanylate cyclase C (GC-C) agonists.

A systematic review found that several antispasmodics, including peppermint oil, pinaverium, trimebutine, and cimetropium/dicyclomine, significantly outperformed placebo at improving irritable bowel syndrome symptom and global assessment scores.[33] Pinaverium and cimetropium are not available in the United States. The National Institutes of Health's (NIH's) National Center for Complementary and Integrative Health (NCCIH) provides information regarding a small amount of research that suggests peppermint oil may improve IBS symptoms.[4]

The 2009 American College of Gastroenterologists (ACG) position statement on the management of irritable bowel syndrome noted that the antidiarrheal agent loperamide effectively reduced stool frequency and improved stool consistency, but it did not relieve pain, bloating, or other global irritable bowel syndrome symptoms.[3] As noted earlier, the 2014 ACG monograph on the management of irritable bowel syndrome and chronic idiopathic constipation found insufficient evidence to recommend prebiotics or synbiotics, or loperamide, in irritable bowel syndrome, and no evidence that polyethylene glycol improved overall symptoms and pain in affected patients.[32] The most recent 2018 ACG monograph on the management of IBS has upheld these aforementioned recommendations.[51]

A Spanish expert consensus panel on functional digestive disorders have made evidence-based recommendations on the use of linaclotide, a GC-C receptor agonist, for the management of the constipation-predominant disease (IBS-C) subtype.[52] Their recommendations include continuous (not sporadic) use of linaclotide therapy for moderate to severe IBS-C, patient education regarding the risk of diarrhea and its management options, and the maintenance of linaclotide therapy for potentially long periods on the basis of the lack of tachyphylaxis or potential risks.[52] In 2018, another GC-C receptor agonist, plecanatide, was approved by the FDA for treatment of IBS-C in adults.[53]

Rifaximin was approved by the FDA in 2015 for IBS-D.[54] A total of 1260 patients with IBS without constipation were enrolled in the TARGET 1 and TARGET 2 phase III trials at 179 investigative sites in the United States and Canada. Results showed that treatment with rifaximin (550 mg PO tid for 14 d) provided better symptom relief (eg, bloating, abdominal pain, loose/watery stools) compared with placebo, although the placebo effect was tremendous. Similarly, a 2012 meta-analysis of five studies, incorporating 1,803 patients, determined that rifaximin is more effective than placebo for global symptom relief and bloating. Adverse event rates were similar to placebo.[55, 56]

Tegaserod was reintroduced in the United States in 2019 after it had been suspended from the market in 2007 because of cardiovascular (CV) safety concerns.[57, 58, 59] The reapproved tegaserod indication is for women younger than 65 years with IBS-C who are without a history of CV ischemic disease and who have a low risk of developing CV disease. FDA approval was based on three multicenter, double-blind, placebo-controlled trials that stratified data from women with IBS-C (N = 2470).[57, 58] Tegaserod has been "shown to improve symptoms, enhance gastric accommodation and significantly attenuate visceral pain arising from the colon in functional dyspepsia patients."[59] Evidence also exists in animal models that tegaserod may have a protective effect in inflamed colons.[59]

Lubiprostone (Amitiza)

Clinical Context:  This agent activates chloride channels on the apical part of the small bowel epithelium. As a result, chloride ions are secreted and sodium and water passively diffuse into the lumen to maintain isotonicity. This medication is FDA approved for use in idiopathic constipation and in irritable bowel syndrome with constipation.

Linaclotide (Linzess)

Clinical Context:  Guanylate cyclase agonist; activation of guanylate cyclase receptors in the intestinal neurons leads to increased cyclic guanosine monophosphate (cGMP), anion secretion, fluid secretion, and intestinal transit; it appears to work topically rather than systemically; when administered PO, linaclotide activates chloride channels in intestinal epithelial cells to increase intestinal fluid secretion; indicated to treat chronic idiopathic constipation and for IBS-C in adults.

Plecanatide (Trulance)

Clinical Context:  Plecanatide is a guanylate cyclase C (GC-C) agonist. Plecanatide and its active metabolite bind to GC-C and act locally on the luminal surface of intestinal epithelial cells. GC-C activation leads to increased cyclic guanosine monophosphate (cGMP), which, in turn, stimulates secretion of chloride and bicarbonate into the intestinal lumen, mainly by activation of the cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid and accelerated transit. It is indicated for IBS-C in adults.

Alosetron (Lotronex)

Clinical Context:  Alosetron is a 5-HT3 receptor antagonist. This agent controls irritable bowel syndrome symptoms through its potent and selective antagonism of serotonin 5-HT3 receptor type. These receptors are extensively located on the enteric neurons of the GI tract, and stimulation causes hypersensitivity and hyperactivity of the intestine. It is indicated only for women with severe diarrhea-predominant IBS who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the GI tract excluded, and have not responded adequately to conventional therapy.

Limiting its use to this severely affected population is intended to maximize the benefit-to-risk ratio. The drug was previously removed from the US market but was reintroduced with new restrictions approved by the FDA on June 7, 2002. Restrictions are because of reports of infrequent but serious GI adverse reactions (eg, ischemic colitis, serious complications of constipation), including some that resulted in hospitalization and, rarely, blood transfusion, surgery, or death. In order to prescribe, physicians must be enrolled in the Prescribing Program for Lotronex.

Under the new management plan, serious adverse events have been few.[28]

Tegaserod (Zelnorm)

Clinical Context:  Tegaserod is a serotonin type-4 (5-hydroxytryptamine-4 [5-HT4]) receptor partial agonist. It stimulates the peristaltic reflex and intestinal secretions, inhibits visceral sensitivity, enhances basal motor activity, and normalizes impaired motility throughout the gastrointestinal tract. It is indicated for adult women younger than 65 years who have irritable bowel syndrome with constipation (IBS-C). Its use is further restricted to women without a history of cardiovascular risk.

Eluxadoline (Viberzi)

Clinical Context:  Eluxadoline is a mu opioid receptor agonist. It also is a delta opioid receptor antagonist and a kappa opioid receptor agonist. The multiple opioid activity is designed to treat the symptoms of IBS-D while reducing the incidence of constipation that can occur with unopposed mu opioid receptor agonists. It is indicated for IBS-D in adult men and women.

Tenapanor (Ibsrela)

Clinical Context:  Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for absorption of dietary sodium. NHE3 inhibition reduces sodium absorption from the small intestine and colon, resulting in an increase in water secretion into the intestinal lumen, which accelerates intestinal transit time and results in a softer stool consistency. It is indicated for adults with IBS-C.

Class Summary

Linaclotide and lubiprostone enhance chloride-rich intestinal fluid secretions without altering the sodium and potassium concentrations in the serum. Linaclotide was approved by the FDA in August 2012 to treat chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults.[60]

The safety and efficacy of linaclotide in the treatment of IBS-C were evaluated in 2 double-blind, placebo-controlled phase III clinical trials in which linaclotide met all four primary endpoints for changes in abdominal pain and constipation in each trial. The trials involved 1,605 patients aged 18-87 years, of which 807 were treated with linaclotide 290 mcg. Both trials showed a significantly higher proportion of responders in the linaclotide group compared with the placebo group.[60, 61, 62]

Tenapanor, an inhibitor of sodium-hydrogen exchange (NHE3) transporter, was approved in September 2019 for IBS-C. Approval was based on two phase III trials (N = 1226) that showed a statistically significant improvement in stool frequency and abdominal pain compared with those who received placebo.[6]

Dicyclomine hydrochloride (Bentyl)

Clinical Context:  Dicyclomine blocks the action of acetylcholine at parasympathetic sites in secretory glands, smooth muscle, and CNS. This drug decreases fecal urgency and pain. It is useful in patients with diarrhea-predominant symptoms. Adverse effects are dose dependent.

Hyoscyamine (Anaspaz, Levbid)

Clinical Context:  Like dicyclomine, hyoscyamine is useful in patients with diarrhea-predominant symptoms and blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS, which, in turn, has antispasmodic effects. The drug decreases fecal urgency and pain.

Class Summary

Anticholinergic agents are antispasmodics that inhibit intestinal smooth-muscle depolarization at the muscarinic receptor. These agents help relieve symptoms of intestinal spasms in irritable bowel syndrome.

Diphenoxylate hydrochloride 2.5 mg with atropine sulfate 0.025 mg (Lomotil)

Clinical Context:  This drug combination consists of 2.5 mg of diphenoxylate, which is a constipating meperidine congener, and 0.025 mg of atropine to discourage abuse. The preparation inhibits excessive GI propulsion and motility, but it may exacerbate constipation.

Loperamide (Imodium)

Clinical Context:  Loperamide, which is available over the counter, acts on intestinal muscles to inhibit peristalsis and to slow intestinal motility. It prolongs the movement of electrolytes and fluid through the bowel and increases the viscosity and loss of fluids and electrolytes. Loperamide improves stool frequency and consistency, reduces abdominal pain and fecal urgency, and may exacerbate constipation.

Class Summary

These agents are nonabsorbable synthetic opioids. They prolong the GI transit time and decrease secretion via peripheral µ-opioid receptors. They reduce visceral nociception via afferent pathway inhibition.

Imipramine (Tofranil)

Clinical Context:  Imipramine increases pain threshold in the gut, thereby providing a visceral analgesic effect. It prolongs oral-cecal transit time; reduces abdominal pain, mucorrhea, and stool frequency; and increases global well-being variably. It is effective in irritable bowel syndrome in doses that are subtherapeutic for antidepressive actions, suggesting an independent mechanism of action in this disorder.

Amitriptyline (Elavil)

Clinical Context:  Like imipramine, amitriptyline provides a visceral analgesic effect at doses subtherapeutic for antidepressive actions. It also prolongs oral-cecal transit time, reduces abdominal pain, mucorrhea, and stool frequency, and increases global well-being variably.

Class Summary

Tricyclic antidepressants have both antidepressive and analgesic properties. Agents such as imipramine and amitriptyline are efficacious in treating symptoms of irritable bowel syndrome. The use of tricyclic antidepressants in irritable bowel syndrome is off label.

Rifaximin (Xifaxan)

Clinical Context:  Rifaximin is a semisynthetic derivative of rifampin and acts by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, blocking one of the steps in transcription. This results in inhibition of bacterial protein synthesis and consequently inhibits the growth of bacteria. The exact mechanism of action for IBS-D is not known, but it is thought to be related to changes in the bacterial content in the gastrointestinal tract and reduction of gas. It is indicated for IBS-D in adult men and women.

Class Summary

Antibiotics may play a role in the treatment of irritable bowel syndrome by preventing the overgrowth of intestinal bacteria.

Methylcellulose (Citrucel)

Clinical Context:  This agent promotes bowel evacuation by forming a viscous liquid and promoting peristalsis.

Psyllium (Metamucil, Fiberall, Reguloid, Konsyl)

Clinical Context:  Like methylcellulose, psyllium promotes bowel evacuation by forming a viscous liquid and promoting peristalsis.

Class Summary

These products are made of natural and semi-synthetic hydrophilic polysaccharides and cellulose derivatives that dissolve or swell in the intestinal fluid, forming emollient gels that facilitate the passage of intestinal contents and stimulate peristalsis. As fiber supplements, these products may improve symptoms of constipation and diarrhea, but their use in irritable bowel syndrome is controversial.

What is irritable bowel syndrome (IBS)?What are the symptoms of irritable bowel syndrome (IBS)?How are bowel habits altered in patients with irritable bowel syndrome (IBS)?What are the characteristics of abdominal pain in irritable bowel syndrome (IBS)?What additional symptoms may accompany altered bowels and abdominal pain in irritable bowel syndrome (IBS)?What symptoms are inconsistent with irritable bowel syndrome (IBS) and suggest an alternative diagnosis?What is the Rome IV criteria for diagnosis of irritable bowel syndrome (IBS)?How are bowel patterns classified by the Rome IV criteria for the diagnosis of irritable bowel (IBS)?What are the ACG recommendations for diagnostic testing in suspected irritable bowel syndrome (IBS)?Which lab tests can be used to differentiate irritable bowel syndrome (IBS) from other disorders?Which history-specific studies are used for the diagnosis of irritable bowel syndrome (IBS)?How is irritable bowel syndrome (IBS) managed?Which dietary measures may help ease the symptoms of irritable bowel syndrome (IBS)?Which psychological therapies are effective in the management of irritable bowel syndrome (IBS)?Which medications are used for the management of irritable bowel syndrome (IBS)?What terms are synonymous with irritable bowel syndrome (IBS)?Is irritable bowel syndrome (IBS) a diagnosis of exclusion?What is the pathophysiology of irritable bowel syndrome (IBS)?What is the pathophysiology of altered GI motility in irritable bowel syndrome (IBS)?What is the pathophysiology of visceral hyperalgesia in irritable bowel syndrome (IBS)?What is the role of psychopathology in irritable bowel syndrome (IBS)?Does inflammation have a role in the pathophysiology of irritable bowel syndrome (IBS)?What are risk factors for postinfectious irritable bowel syndrome (IBS)?What laparoscopic full-thickness jejunal biopsy findings suggest irritable bowel syndrome (IBS)?Which findings suggest postinfectious irritable bowel syndrome (IBS)?What is the role of bacterial overgrowth in irritable bowel syndrome (IBS)?What causes irritable bowel syndrome (IBS)?What are possible infection-related causes of irritable bowel syndrome (IBS)?What are the central neurohormonal mechanisms by which irritable bowel syndrome (IBS) occurs?How does irritable bowel syndrome (IBS) affect intestinal permeability?How does bowel bacterial overgrowth affect irritable bowel syndrome (IBS)?How do dietary intolerances affect the symptoms of irritable bowel syndrome (IBS)?What is the prevalence and incidence of irritable bowel syndrome (IBS)?How many people with irritable bowel syndrome (IBS) seek medical care?What are the sexual, ethnic, and racial differences in irritable bowel syndrome (IBS) incidence?In what age group is the onset of irritable bowel syndrome (IBS) symptoms most common?What is the prognosis of irritable bowel syndrome (IBS)?What are the benefits of patient education in the management of irritable bowel syndrome (IBS)?How is irritable bowel syndrome (IBS) diagnosed?Which altered bowel habits indicate irritable bowel syndrome (IBS)?How does abdominal pain present in irritable bowel syndrome (IBS)?Which abdominal bloating/distention findings indicate irritable bowel syndrome (IBS)?In addition to altered bowels, abdominal pain, and bloating, which symptoms may indicate irritable bowel syndrome (IBS)?Which symptoms are inconsistent with irritable bowel syndrome (IBS)?What physical findings are typical in irritable bowel syndrome (IBS)?What is the updated Rome IV criteria for diagnosis of irritable bowel syndrome (IBS)?How is irritable bowel syndrome (IBS) differentiated from organic bowel disease?What are the differential diagnoses for Irritable Bowel Syndrome (IBS)?When are lab testing and diagnostic imaging necessary for diagnosis of irritable bowel syndrome (IBS)?What is the role of blood tests in the evaluation of suspected irritable bowel syndrome (IBS)?Which stool exams are useful in the evaluation of suspected irritable bowel syndrome (IBS)?What is the role of hydrogen breath testing in the evaluation of suspected irritable bowel syndrome (IBS)?Are thyroid function tests used in the evaluation of suspected irritable bowel syndrome (IBS)?Are erythrocyte sedimentation rate and C-reactive protein measurement used in the evaluation of suspected irritable bowel syndrome (IBS)?When are imaging studies considered in the evaluation of suspected irritable bowel syndrome (IBS)?Which dietary studies may be helpful in the evaluation of suspected irritable bowel syndrome (IBS)?What is the purpose of anal manometry in the evaluation of suspected irritable bowel syndrome (IBS)?When is esophagogastroduodenoscopy or colonoscopy indicated in the diagnosis of irritable bowel syndrome (IBS)?What are the treatment options for irritable bowel syndrome (IBS)?What are the ACG recommendations on the management of irritable bowel syndrome (IBS)?What information should be given to patients with irritable bowel syndrome (IBS)?Is fiber supplementation beneficial in the management of irritable bowel syndrome (IBS)?Are there water intake recommendations in patients with irritable bowel syndrome (IBS)?What foods should be avoided by patients with irritable bowel syndrome (IBS)?What is the relationship between gluten intolerance and irritable bowel syndrome (IBS)?Which diets reduce symptoms of irritable bowel syndrome (IBS)?Is psychological therapy effective for the management of irritable bowel syndrome (IBS)?Is cognitive-behavioral therapy (CBT) or interpersonal psychotherapy effective in the treatment of irritable bowel syndrome (IBS)?Are antidepressants effective in the treatment of irritable bowel syndrome (IBS)?What is the ACG position on psychological interventions for irritable bowel syndrome (IBS)?Is long-term monitoring required in irritable bowel syndrome (IBS)?How are medications for irritable bowel syndrome (IBS) selected?Are antispasmodics effective in the treatment of irritable bowel syndrome (IBS)?Is loperamide beneficial in the treatment of irritable bowel syndrome (IBS)?What are the evidence-based recommendations on the use of linaclotide in the treatment of irritable bowel syndrome (IBS)?Is rifaximin or tegaserod effective in the treatment of irritable bowel syndrome (IBS)?Which medications in the drug class IBS Agents are used in the treatment of Irritable Bowel Syndrome (IBS)?Which medications in the drug class Anticholinergics are used in the treatment of Irritable Bowel Syndrome (IBS)?Which medications in the drug class Antidiarrheals are used in the treatment of Irritable Bowel Syndrome (IBS)?Which medications in the drug class Tricyclic Antidepressants are used in the treatment of Irritable Bowel Syndrome (IBS)?Which medications in the drug class Antibiotics are used in the treatment of Irritable Bowel Syndrome (IBS)?Which medications in the drug class Bulk-Forming Laxatives are used in the treatment of Irritable Bowel Syndrome (IBS)?

Author

Jenifer K Lehrer, MD, Attending Physician, Department of Gastroenterology, Jefferson Health System Torresdale Campus, Philadelphia

Disclosure: Nothing to disclose.

Coauthor(s)

Gary R Lichtenstein, MD, Professor of Medicine, Director, Center for Inflammatory Bowel Disease, Department of Medicine, Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Abbott Corp/Abbvie; Actavis; Alaven; CellCeutrix; Celgene; Ferring; Gilead; Hospira; Janssen Orthobiotech; Luitpold/American Regent; Pfizer Pharm; Prometheus Labs; Romark; Salix Pharma/Valeant; Santarus/Receptos/Celgene; Shire Pharma; Takeda; UCB<br/>Received research grant from: Salix Pharm/Valeant; Santarus/Receptos/Celgene; Shire Pharm; UCB<br/>Received author or editor honorarium or book royalty from for: Clinical Advances in Gastroenterology; Gastroenterology and Hepatology; Gastro-Hep Communications; Ironwood; Luitpold/American Regent; Merck; McMahon Publishing; Romark; SLACK Inc; Springer Science and Business Media; Up-To-Date.

Specialty Editors

Mary L Windle, PharmD, Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

BS Anand, MD, Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Rajeev Vasudeva, MD, FACG Clinical Professor of Medicine, Consultants in Gastroenterology, University of South Carolina School of Medicine

Rajeev Vasudeva, MD, FACG is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy, Columbia Medical Society, South Carolina Gastroenterology Association, and South Carolina Medical Association

Disclosure: Pricara Honoraria Speaking and teaching; UCB Consulting fee Consulting

References

  1. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease?. Gastroenterol Clin North Am. 2005 Jun. 34(2):235-45, vi-vii. [View Abstract]
  2. Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017 Apr 30. 23(2):151-63. [View Abstract]
  3. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al, for the American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol. 2009 Jan. 104 suppl 1:S1-35. [View Abstract]
  4. National Center for Complementary and Integrative Health. Peppermint oil. Available at https://nccih.nih.gov/health/peppermintoil. September 2016; Accessed: April 2, 2019.
  5. Trulance (plecanatide) [package insert]. New York, NY: Synergy Pharmaceuticals Inc. January, 2018. Available at
  6. Chey WD, Lembo AJ, Yan A, Rosenbaum DP. Efficacy and safety of tenapanor in patients with constipation predominant irritable bowel syndrome: a 6-month, double-blind, placebo-controlled phase 3 trial (T3MPO-2) [abstract 885]. Presented at: Digestive Disease Week; June 2-5, 2018; Washington, DC. Gastroenterology. 2018 May. 54(6 suppl 1):S-1362.
  7. Spiegel BM, Farid M, Esrailian E, Talley J, Chang L. Is irritable bowel syndrome a diagnosis of exclusion? A survey of primary care providers, gastroenterologists, and IBS experts. Am J Gastroenterol. 2010 Apr. 105(4):848-58. [View Abstract]
  8. Chumpitazi BP, Shulman RJ. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Mol Cell Pediatr. 2016 Dec. 3(1):11. [View Abstract]
  9. Quigley EMM. The gut-brain axis and the microbiome: clues to pathophysiology and opportunities for novel management strategies in irritable bowel syndrome (IBS). J Clin Med. 2018 Jan 3. 7(1):[View Abstract]
  10. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016 Oct 30. 22(4):558-74. [View Abstract]
  11. Miller V, Hopkins L, Whorwell PJ. Suicidal ideation in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004 Dec. 2(12):1064-8. [View Abstract]
  12. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May. 136(6):1979-88. [View Abstract]
  13. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology. 2002 Dec. 123(6):1972-9. [View Abstract]
  14. Kassinen A, Krogius-Kurikka L, Makivuokko H, et al. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007 Jul. 133(1):24-33. [View Abstract]
  15. Camilleri M. Functional gastrointestinal disorders: novel insights and treatments. Medscape General Medicine. Available at http://www.medscape.com/viewarticle/717346. 1999;1(3); Accessed: September 20, 2010.
  16. Wensaas KA, Langeland N, Hanevik K, Morch K, Eide GE, Rortveit G. Irritable bowel syndrome and chronic fatigue 3 years after acute giardiasis: historic cohort study. Gut. 2012 Feb. 61(2):214-9. [View Abstract]
  17. Lacy BE. The science, evidence, and practice of dietary interventions in irritable bowel syndrome. Clin Gastroenterol Hepatol. 2015 Nov. 13(11):1899-906. [View Abstract]
  18. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003 Feb. 98(2):412-9. [View Abstract]
  19. Quigley EMM. Are diets the answers to colon ills? Food, irritable bowel syndrome and the microbiome. Curr Opin Gastroenterol. 2018 Mar. 34(2):103-4. [View Abstract]
  20. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008 Jul. 6(7):765-71. [View Abstract]
  21. Chumpitazi BP, McMeans AR, Vaughan A, et al. Fructans exacerbate symptoms in a subset of children with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2018 Feb. 16(2):219-25.e1. [View Abstract]
  22. Henstrom M, Diekmann L, Bonfiglio F, et al. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. Gut. 2018 Feb. 67(2):263-70. [View Abstract]
  23. Garcia-Etxebarria K, Zheng T, Bonfiglio F, et al. Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients. Clin Gastroenterol Hepatol. 2018 Oct. 16(10):1673-6. [View Abstract]
  24. Knowles SR, Austin DW, Sivanesan S, et al. Relations between symptom severity, illness perceptions, visceral sensitivity, coping strategies and well-being in irritable bowel syndrome guided by the common sense model of illness. Psychol Health Med. 2017 Jun. 22(5):524-34. [View Abstract]
  25. Palsson OS, van Tilburg MA, Simren M, Sperber AD, Whitehead WE. Population prevalence of Rome IV and Rome III irritable bowel syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK) [abstract Mo1642]. Gastroenterology. Apr 2016. 150(4 suppl 1):S739-40.
  26. Khashan AS, Quigley EM, McNamee R, McCarthy FP, Shanahan F, Kenny LC. Increased risk of miscarriage and ectopic pregnancy among women with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2012 Aug. 10(8):902-9. [View Abstract]
  27. Silvernale C, Kuo B, Staller K. Lower socioeconomic status is associated with an increased prevalence of comorbid anxiety and depression among patients with irritable bowel syndrome: results from a multicenter cohort. Scand J Gastroenterol. 2019 Sep. 54(9):1070-4. [View Abstract]
  28. Han CJ, Pike K, Jarrett ME, Heitkemper MM. Symptom-based latent classes of persons with irritable bowel syndrome. Res Nurs Health. 2019 Oct. 42(5):382-91. [View Abstract]
  29. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J. 1978 Sep 2. 2(6138):653-4. [View Abstract]
  30. Sood R, Camilleri M, Gracie DJ, et al. Enhancing diagnostic performance of symptom-based criteria for irritable bowel syndrome by additional history and limited diagnostic evaluation. Am J Gastroenterol. 2016 Oct. 111(10):1446-54. [View Abstract]
  31. Almazar AE, Talley NJ, Larson JJ, Atkinson EJ, Murray JA, Saito YA. Celiac disease is uncommon in irritable bowel syndrome in the USA. Eur J Gastroenterol Hepatol. 2018 Feb. 30(2):149-54. [View Abstract]
  32. Ford AC, Moayyedi P, Lacy BE, et al, for the Task Force on the Management of Functional Bowel Disorders. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014 Aug. 109 suppl 1:S2-26; quiz S27. [View Abstract]
  33. Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011 Aug 10. CD003460. [View Abstract]
  34. Biesiekierski JR, Newnham ED, Irving PM, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am J Gastroenterol. 2011 Mar. 106(3):508-14; quiz 515. [View Abstract]
  35. Volta U, Pinto-Sanchez MI, Boschetti E, Caio G, De Giorgio R, Verdu EF. Dietary triggers in irritable bowel syndrome: is there a role for gluten?. J Neurogastroenterol Motil. 2016 Oct 30. 22(4):547-57. [View Abstract]
  36. Gibson PR, Varney J, Malakar S, Muir JG. Food components and irritable bowel syndrome. Gastroenterology. 2015 May. 148(6):1158-74.e4. [View Abstract]
  37. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014 Jan. 146(1):67-75.e5. [View Abstract]
  38. Valeur J, Smastuen MC, Knudsen T, Lied GA, Roseth AG. Exploring gut microbiota composition as an indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome. Dig Dis Sci. 2018 Feb. 63(2):429-36. [View Abstract]
  39. Tuck CJ, Caminero A, Jimenez Vargas NN, et al. The impact of dietary fermentable carbohydrates on a postinflammatory model of irritable bowel syndrome. Neurogastroenterol Motil. 2019 Oct. 31(10):e13675. [View Abstract]
  40. Nawawi KNM, Belov M, Goulding C. Low FODMAP diet significantly improves IBS symptoms: an Irish retrospective cohort study. Eur J Nutr. 2019 Sep 13. [View Abstract]
  41. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 Mar. 59(3):325-32. [View Abstract]
  42. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology. 2014 May. 146(6):1554-63. [View Abstract]
  43. Principi N, Cozzali R, Farinelli E, Brusaferro A, Esposito S. Gut dysbiosis and irritable bowel syndrome: The potential role of probiotics. J Infect. 2018 Feb. 76(2):111-20. [View Abstract]
  44. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol. 2009 Apr. 104(4):1033-49; quiz 1050. [View Abstract]
  45. Liu HN, Wu H, Chen YZ, Chen YJ, Shen XZ, Liu TT. Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: A systematic review and meta-analysis. Dig Liver Dis. 2017 Apr. 49(4):331-7. [View Abstract]
  46. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014 Oct. 109(10):1547-61; quiz 1546, 1562. [View Abstract]
  47. Cremon C, Stanghellini V, Barbaro MR, et al. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Apr. 45(7):909-22. [View Abstract]
  48. Khayyatzadeh SS, Kazemi-Bajestani SMR, Mirmousavi SJ, et al. Dietary behaviors in relation to prevalence of irritable bowel syndrome in adolescent girls. J Gastroenterol Hepatol. 2018 Feb. 33(2):404-10. [View Abstract]
  49. Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst Rev. 2009 Jan 21. CD006442. [View Abstract]
  50. Ford AC, Talley NJ, Schoenfeld PS, Quigley EM, Moayyedi P. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut. 2009 Mar. 58(3):367-78. [View Abstract]
  51. [Guideline] Ford AC, Moayyedi P, Chey WD, et al, for the ACG Task Force on Management of Irritable Bowel Syndrome. American College of Gastroenterology monograph on management of irritable bowel syndrome. Am J Gastroenterol. 2018 Jun. 113(suppl 2):1-18. [View Abstract]
  52. Rey E, Mearin F, Alcedo J, et al. Optimizing the use of linaclotide in patients with constipation-predominant irritable bowel syndrome: an expert consensus report. Adv Ther. 2017 Mar. 34(3):587-98. [View Abstract]
  53. Synergy Pharmaceuticals. Synergy Pharmaceuticals announces FDA approval of Trulance (plecanatide) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults [press release]. Available at https://ir.synergypharma.com/press-releases/detail/1861/synergy-pharmaceuticals-announces-fda-approval-of. January 25, 2018; Accessed: January 25, 2018.
  54. Valeant Pharmaceuticals International, Inc. Salix announces FDA approval of Xifaxan 550 mg for the treatment of IBS-D (irritable bowel syndrome with diarrhea). Cision PR Newswire. Available at https://www.prnewswire.com/news-releases/salix-announces-fda-approval-of-xifaxan-550-mg-for-the-treatment-of-ibs-d-irritable-bowel-syndrome-with-diarrhea-300089821.html. May 27, 2015; Accessed: June 6, 2015.
  55. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012 Jan. 107(1):28-35; quiz 36. [View Abstract]
  56. Pimentel M, Lembo A, Chey WD, et al, for the TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011 Jan 6. 364(1):22-32. [View Abstract]
  57. Zelnorm (tegaserod) [package insert]. Louisville, KY: Sloan Pharma. March 2019. Available at
  58. Brooks M. FDA OKs reintroduction of tegaserod (Zelnorm) for IBS-C in women under 65. Medscape Medical News. Available at http://medscape.com/viewarticle/911237. April 2, 2019; Accessed: April 2, 2019.
  59. Madia VN, Messore A, Saccoliti F, et al. Tegaserod for the treatment of irritable bowel syndrome. Antiinflamm Antiallergy Agents Med Chem. 2019 Sep 11. [View Abstract]
  60. US Food and Drug Administration. FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation. August 30, 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm317505.htm. Accessed: May 12, 2015.
  61. Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012 Nov. 107(11):1714-24; quiz p.1725. [View Abstract]
  62. Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012 Nov. 107(11):1702-12. [View Abstract]
  63. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006 Apr. 130(5):1480-91. [View Abstract]
  64. Chang L, Tong K, Ameen V. Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences. Am J Gastroenterol. 2010 Apr. 105(4):866-75. [View Abstract]
  65. Drossman DA, Corazziari E, Delvaux M, et al. Rome Foundation diagnostic algorithms. Appendix A: Psychosocial alarm questionnaire for the functional GI disorders. Am J Gastro. Apr 2010. 105(4): 795-7.
  66. Vazquez-Roque MI, Camilleri M, Smyrk T, et al. A controlled trial of gluten-free diet in patients with irritable bowel syndrome-diarrhea: effects on bowel frequency and intestinal function. Gastroenterology. 2013 May. 144 (5):903-11.e3. [View Abstract]
  67. Henstrom M, D'Amato M. Genetics of irritable bowel syndrome. Mol Cell Pediatr. 2016 Dec. 3(1):7. [View Abstract]
  68. Boersma K, Ljotsson B, Edebol-Carlman H, Schrooten M, Linton SJ, Brummer RJ. Exposure-based cognitive behavioral therapy for irritable bowel syndrome. A single-case experimental design across 13 subjects. Cogn Behav Ther. 2016 Nov. 45(6):415-30. [View Abstract]
  69. Blake MR, Raker JM, Whelan K. Validity and reliability of the Bristol Stool Form Scale in healthy adults and patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2016 Oct. 44(7):693-703. [View Abstract]
  70. Miner PB Jr. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome. Expert Opin Pharmacother. 2018 Feb. 19(2):177-83. [View Abstract]
  71. Black CJ, Ford AC, Houghton LA. Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer?. Aliment Pharmacol Ther. 2019 Oct. 50(7):825-6. [View Abstract]
  72. Gunn D, Garsed K, Lam C, et al. Editorial: understanding differences in patient response to ondansetron in irritable bowel syndrome with diarrhoea-are we any closer? Authors' reply. Aliment Pharmacol Ther. 2019 Oct. 50(7):826-7. [View Abstract]

What is irritable bowel syndrome (IBS)? IBS is a condition that involves recurrent abdominal pain as well as abnormal bowel motility, which can include diarrhea and/or constipation.

What is irritable bowel syndrome (IBS)? IBS is a condition that involves recurrent abdominal pain as well as abnormal bowel motility, which can include diarrhea and/or constipation.

What is irritable bowel syndrome (IBS)? IBS is a condition that involves recurrent abdominal pain as well as abnormal bowel motility, which can include diarrhea and/or constipation.